Notices

- Revised: Notice of NIH’s Interest in Diversity (NOT-OD-18-129) National Institutes of Health

- Grant Application Due Dates Following the Receipt Lapse in Appropriations (NOT-OD-18-131) National Institutes of Health

- Notice of Corrected Expiration Date of PA-17-285 "Understanding Processes of Recovery in the Treatment of Alcohol Use Disorder (R01)" (NOT-AA-18-001) National Institute on Alcohol Abuse and Alcoholism

- Notice of Corrected Expiration Date of PA-17-284 "Understanding Processes of Recovery in the Treatment of Alcohol Use Disorder (R21)" (NOT-AA-18-002) National Institute on Alcohol Abuse and Alcoholism

- Notice of Expiration of PAR-17-056 "Investigator Initiated Extended Clinical Trial (R01)" (NOT-AI-18-012) National Institute of Allergy and Infectious Diseases National Institute on Aging National Institute of General Medical Sciences

- Notice of Expiration of PAR-16-270 "NIAID Clinical Trial Implementation Cooperative Agreement (U01)" (NOT-AI-18-013) National Institute of Allergy and Infectious Diseases

- Notice of Expiration of PAR-16-271 "NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44)" (NOT-AI-18-014) National Institute of Allergy and Infectious Diseases

- Notice of Correction to PA-18-517, "Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp - Clinical Trial Not Allowed)" (NOT-CA-18-035) National Cancer Institute

- NCI Method to Extend Research in Time (MERIT) Award for Early Stage Investigators (R37) (NOT-CA-18-037) National Cancer Institute
• Notice of Expiration of PAR-15-308, "Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (R01)"
  (NOT-CA-18-038)
  National Cancer Institute

• Notice of Expiration of PAR-15-309, "Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (R21)"
  (NOT-CA-18-039)
  National Cancer Institute

• Notice of Expiration of PAR-16-249, "Innovative Approaches to Studying Cancer Communication in the New Media Environment (R01)"
  (NOT-CA-18-040)
  National Cancer Institute

• Notice of Expiration of PAR-17-124 "Perception and Cognition Research to Inform Cancer Image Interpretation (R21)"
  (NOT-CA-18-042)
  National Cancer Institute

• Notice of Expiration of PAR-17-125 "Perception and Cognition Research to Inform Cancer Image Interpretation (R01)"
  (NOT-CA-18-043)
  National Cancer Institute

• Notice of Expiration of PAR-16-212 "Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01)"
  (NOT-CA-18-044)
  National Cancer Institute

• Notice of Expiration of PAR-16-213 "Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21)"
  (NOT-CA-18-045)
  National Cancer Institute

• Notice of Expiration of PAR-17-217 "U.S. Tobacco Control Policies to Reduce Health Disparities (R01)"
  (NOT-CA-18-046)
  National Cancer Institute

• Notice of Expiration of PAR-17-218 "U.S. Tobacco Control Policies to Reduce Health Disparities (R21)"
  (NOT-CA-18-047)
  National Cancer Institute

• Notice of Expiration for RFA-CA-17-019, "Revision Applications to NCI-supported R01 Awards to Include Research on the NCI's Provocative Questions (R01)"
  (NOT-CA-18-048)
  National Cancer Institute
• Notice of Expiration for RFA-CA-17-020, "Revision Applications to National Cancer Institute (NCI)-supported U01 Awards to Include Research on the NCI's Provocative Questions (U01)"
  (NOT-CA-18-049)
  National Cancer Institute

• Notice of Expiration for RFA-CA-17-021, "Revision Applications to National Cancer Institute (NCI)-supported P01 Awards to Include Research on the NCI's Provocative Questions (P01)"
  (NOT-CA-18-050)
  National Cancer Institute

• Notice of Expiration for RFA-CA-17-022, "Revision Applications to National Cancer Institute (NCI)-supported P50 Awards to Include Research on the NCI's Provocative Questions (P50)"
  (NOT-CA-18-051)
  National Cancer Institute

• Notice of Expiration of RFA-CA-17-017, "Research Answers to NCI's Provocative Questions (R01)"
  (NOT-CA-18-053)
  National Cancer Institute

• Notice of Expiration of RFA-CA-17-018, "Research Answers to NCI's Provocative Questions (R21)"
  (NOT-CA-18-054)
  National Cancer Institute

• Notice of Corrected Expiration Date for NIDA RFA-DA-18-002, "Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01)"
  (NOT-DA-18-002)
  National Institute on Drug Abuse

• Notice of Change to Expiration Date for PAR-16-348 "Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03)"
  (NOT-HD-18-001)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development

• Notice of Change to Expiration Date for PAR-16-323 "Small Research Grants for Establishing Basic Science-Clinical Collaborations to Understand Structural Birth Defects (R03)"
  (NOT-HD-18-002)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development

• Request for Information (RFI): Strategically Critical Resources or Infrastructures Recommended for NHLBI Support Using the R24/U24 Grant Mechanisms
  (NOT-HL-17-571)
  National Heart, Lung, and Blood Institute

• Notice of Correction of Key Dates for PAR-17-004 "Secondary Analyses of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21)"
  (NOT-HL-18-583)
  National Heart, Lung, and Blood Institute
• Notice of Expiration of RFA-HL-17-012 "Small Market Awards: SBIR Phase IIB Competing Renewals for Heart, Lung, Blood, and Sleep Technologies with Small Commercial Markets (R44)"
  (NOT-HL-18-584)
  National Heart, Lung, and Blood Institute

• NHLBI Announces Webinar for PAR-18-577, New Epidemiology Cohort Studies in Heart, Lung, Blood, and Sleep Diseases and Disorders (U01 - Clinical Trial Not Allowed)
  (NOT-HL-18-587)
  National Heart, Lung, and Blood Institute

• Reminder to AHRQ Grantees that FY2013 Funds will Expire on September 30, 2018
  (NOT-HS-18-005)
  Agency for Healthcare Research and Quality

• Notice of Intent to Publish a Funding Opportunity Announcement for A Practice-Based Research Network to Transform Mental Health Care: Science, Service Delivery & Sustainability (U19 Clinical Trial Required)
  (NOT-MH-18-014)
  National Institute of Mental Health

• Notice of Corrected Expiration Date for NIMH PAR-16-389, NIMH Career Transition Award for Tenure- Track and Tenured Intramural Investigators (K22)
  (NOT-MH-18-015)
  National Institute of Mental Health

• Notice of Corrected Expiration Date of NIMH, PAR-16-354, "Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers (P50)"
  (NOT-MH-18-016)
  National Institute of Mental Health

• Notice of Corrected Expiration Date for PAR-17-168, "Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50)"
  (NOT-MH-18-017)
  National Institute of Mental Health

• Notice of Corrected Expiration Date for RFA-MH-18-200, "NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01)"
  (NOT-MH-18-018)
  National Institute of Mental Health

• Notice of Corrected Expiration Date to PA-17-328, " NIMH Administrative Supplement Program to Enable Continuity of Research Experiences of MD/PhDs during Clinical Training (Admin Supp)"
  (NOT-MH-18-020)
  National Institute of Mental Health

• Notice of Corrected Expiration Date for PA-17-165, " Research to Support the Reduction and Elimination of Mental Health Disparities (Admin Supp)"
  (NOT-MH-18-021)
  National Institute of Mental Health
• Notice of Corrected Expiration Date for PA-16-112 "Biomarkers Discovery in Parkinsonism (U01)"
  (NOT-NS-18-038)
  National Institute of Neurological Disorders and Stroke

Requests for Applications

• Alzheimer's Disease Research Centers (P30 - Clinical Trials Not Allowed)  
  (RFA-AG-19-001)
  National Institute on Aging
  Application Receipt Date(s): June 4, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• The Human BioMolecular Atlas Program (HuBMAP) Integration, Visualization and Engagement (HIVE) Initiative (OT2 Clinical Trials Not Allowed)  
  (RFA-RM-18-001)
  The Common Fund/Office of Strategic Coordination
  Application Receipt Date(s): After acceptance of the corresponding required Letter of Intent (LOI) applications are due April 16, 2018), by 5:00 PM local time of applicant organization.

• Rodent Testing Centers for Development of Reporter Systems and Evaluation of Somatic Cell Genome Editing Tools (U42 Clinical Trial Not Allowed)  
  (RFA-RM-18-012)
  The Common Fund/Office of Strategic Coordination
  Application Receipt Date(s): April 3, 2018), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• Development of Large Animal Reporter Systems for Testing Somatic Cell Genome Editing Tools (U24 Clinical Trial Not Allowed)  
  (RFA-RM-18-013)
  The Common Fund/Office of Strategic Coordination
  Application Receipt Date(s): April 3, 2018), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- Development of Cell and Tissue Platforms to Detect Adverse Biological Consequences of Somatic Cell Gene Editing (U01 Clinical Trial Not Allowed) *(RFA-RM-18-015)*

The Common Fund/Office of Strategic Coordination

Application Receipt Date(s): April 3, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Innovative Technologies to Deliver Genome Editing Machinery to Disease-relevant Cells and Tissues (UG3/UH3 Clinical Trial Not Allowed) *(RFA-RM-18-016)*

The Common Fund/Office of Strategic Coordination

Application Receipt Date(s): April 3, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Expanding the Human Genome Editing Repertoire (U01 Clinical Trial Not Allowed) *(RFA-RM-18-017)*

The Common Fund/Office of Strategic Coordination

National Institute of Allergy and Infectious Diseases

Application Receipt Date(s): April 3, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

- Somatic Cell Genome Editing Dissemination and Coordinating Center (U24 Clinical Trial Not Allowed) *(RFA-RM-18-018)*

The Common Fund/Office of Strategic Coordination

National Human Genome Research Institute

Application Receipt Date(s): April 3, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
Program Announcements

- Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
  (PA-18-586)
  National Institutes of Health
  John E. Fogarty International Center
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  National Library of Medicine
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  The Common Fund/Office of Strategic Coordination

Application Receipt/Submission Date(s): Due dates vary by awarding IC. See Table of IC-Specific Information, Requirements and Staff Contacts for more details. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
  (PA-18-589)
  National Institutes of Health
  John E. Fogarty International Center
  National Center for Advancing Translational Sciences
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
Change of Grantee Organization (Type 7 Parent Clinical Trial Optional)
(PA-18-590)

Application Receipt/Submission Date(s): A successor-in-interest request must be made before the anticipated start date at the new organization and preferably several months in advance.

Change of Grantee Organization (Type 7 Parent Clinical Trial Optional)
(PA-18-590)

Application Receipt/Submission Date(s): A change of grantee organization request must be made before the anticipated start date at the new organization and preferably several months in advance.
• Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp - Clinical Trial Optional)  
(PA-18-591)  
National Institutes of Health  
John E. Fogarty International Center  
National Center for Advancing Translational Sciences  
National Center for Complementary and Integrative Health  
National Cancer Institute  
National Eye Institute  
National Human Genome Research Institute  
National Heart, Lung, and Blood Institute  
National Institute on Aging  
National Institute on Alcohol Abuse and Alcoholism  
National Institute of Allergy and Infectious Diseases  
National Institute of Arthritis and Musculoskeletal and Skin Diseases  
National Institute of Biomedical Imaging and Bioengineering  
_Eunice Kennedy Shriver_ National Institute of Child Health and Human Development  
National Institute on Drug Abuse  
National Institute on Deafness and Other Communication Disorders  
National Institute of Dental and Craniofacial Research  
National Institute of Diabetes and Digestive and Kidney Diseases  
National Institute of Environmental Health Sciences  
National Institute of General Medical Sciences  
National Institute of Mental Health  
National Institute on Minority Health and Health Disparities  
National Institute of Neurological Disorders and Stroke  
National Institute of Nursing Research  
National Library of Medicine  
Office of Behavioral and Social Science Research  
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs  
Office of Research on Women’s Health  
The Common Fund/Office of Strategic Coordination  
Application Receipt/Submission Date(s): Due dates may vary by awarding IC. See the awarding IC web site for any applicable Application Due Dates.

• Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp - Clinical Trial Not Allowed )  
(PA-18-592)  
National Institutes of Health  
National Center for Complementary and Integrative Health  
National Cancer Institute  
National Eye Institute  
National Human Genome Research Institute  
National Institute on Aging  
National Institute on Alcohol Abuse and Alcoholism  
National Institute of Allergy and Infectious Diseases  
National Institute of Arthritis and Musculoskeletal and Skin Diseases  
National Institute of Biomedical Imaging and Bioengineering  
_Eunice Kennedy Shriver_ National Institute of Child Health and Human Development  
National Institute on Drug Abuse  
National Institute on Deafness and Other Communication Disorders
Pragmatic Trials for Dementia Care in Long-term Services and Support (LTSS) Settings (R61/R33 - Clinical Trial Required) (PAR-18-585)
National Institute on Aging
Application Receipt/Submission Date(s): March 27, 2018; February 20, 2019; and February 20, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Assistive Technology for Persons with Alzheimer's Disease and Related Dementias and Their Caregivers (R41/R42 - Clinical Trials Optional) (PAR-18-587)
National Institute on Aging
Application Receipt/Submission Date(s): April 10, 2018, January 8, 2019, and January 8, 2020, by 5:00 PM local time of applicant organization.

Assistive Technology for Persons with Alzheimer's Disease and Related Dementias and Their Caregivers (R43/R44 - Clinical Trial Optional) (PAR-18-588)
National Institute on Aging
Application Receipt/Submission Date(s): April 10, 2018, January 8, 2019, and January 8, 2020, by 5:00 PM local time of applicant organization.

NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) (PAR-18-594)
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Application Receipt/Submission Date(s): March 27, 2018; July 2, 2018; November 2, 2018; March 4, 2019; July 2, 2019; November 4, 2019; March 3, 2020, July 2, 2020, November 3, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required) (PAR-18-595)
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Application Receipt/Submission Date(s): March 27, 2018, July 2, 2018; November 2, 2018,
March 4, 2019, July 2, 2019; November 4, 2019 March 3, 2020, July 2, 2020, November 3, 2020 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

You have received this information as a result of being subscribed to the UTHSCSA Office of Sponsored Programs fundinginfo2 ListServ. To remove yourself from this list, visit the Subscriber’s Corner in the List Archives http://lists.uthscsa.edu/scripts/wa.exe?A0=FUNDINGINFO2, and follow the onscreen instructions to log in and manage your list subscriptions.